Genes y Artritis Reumatoidea, Conclusión

La AR es una enfermedad frecuente, crónica y de curso variable. Las características epidemiológicas pueden ser diferentes en función del grupo étnico estudiado. La AR puede ser una enfermedad grave y costosa, por lo tanto, el estudio de los factores que influyen sobre su curso es importante no sólo para el médico, sino también para el paciente y para la sociedad. Los estudios hasta ahora adelantados sobre la enfermedad en Colombia son escasos y, en su mayoría, son descriptivos y reportados en resúmenes21. La investigación de los diferentes factores asociados a la susceptibilidad y gravedad de la AR en nuestro medio mejorará el conocimiento de la misma y permitirá un mejor manejo, dado que los pacientes con mayor riesgo de severidad podrán ser detectados con argumentos basados en estos estudios y tratados consecuentemente.

Referencias

1. Garrod AB. The nature and treatment of gout and rheumatic gout. London: Walton and Moberly, 1859
2. Landré-Beauvais AJ. Doit-on admettre une nouvelle espece de goutte sous la denomination de goutte primitive asthenique?. Thesis, Paris, 1800
3. Tamisier JN, Thomas Ph, Duruy B. Diagnostic rétrospectif de la condition rhumatologique de Madame de Sévigné. En: Appelboom T, ed. Les affections rhumatismales dans l’art et dans l’histoire. Bruselas: René Malherbe, 1988, p.78-79
4. Anaya JM, Correa P, Mantilla RD, Jiménez F, Kuffner T, McNicholl JM. Prevalencia y severidad de la artritis reumatoidea en población afrocolombiana de Quibdó. Acta Med Colomb 1998; 23: 322-333.
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
6. Gabriel SE. The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37: 821-823.
7. Nissila M, Isomaki H, Kaarela K, et al. Prognosis of inflammatory joint diseases. A three year follow-up study. Scand J Rheumatol 1983; 12: 33-38.
8. Eberhardt KB, Rydgen LC, Petterson H, Wollheim FA. Early rheumatoid arthritis _ onset, course and outcome over two years. Rheum Int 1990; 10: 135-142.
9. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-1315.
10. Silman AJ, Hochber MC. Rheumatoid arthritis. En : Silman AJ, Hochber MC, eds. Epidemiology of the Rheumatic Diseases. New York: Oxford University Press; 1993: 7-68.
11. Alarcón GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 589-604
12. Lawrence RC, Helmick CH G, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799
13. Drosos AA, Alamanos I, Voulgari PV, et al. Epidemiology of adult rheumatoid arthritis in Northwest Greece 1987-1995. J Rheumatol 1997; 24: 2129-2133.
14. Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari study. Ann Rheum Dis 1998; 57: 315-318.
15. Louvot J, Flipo RM, Le Dantec L, et al. Prevalence of rheumatoid arthritis in France: a study in the urban area of Lille (resumen). Revue Rheum 1996; 63: 702.
16. Willkens RF, Blandau RL, Aoyama DT, et al. Studies of rheumatoid arthritis among a tribe of Northwest Indians. J Rheumatol 1976; 3: 9-14.
17. Harvey J, Arnett FC, Bias WB et al. Heterogeneity of HLA-DR4 in the rheumatoid arthritis of a Chippewa band. J Rheumatol 1981; 8: 797-803.
18. Del Puente A, Knowler WC, Pettitt DJ, et al. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 1989; 129: 1170-1178.
19. Silman AJ, Ollier W, Holligan S, et al. Abserce of rheumatoid arthritis in a rural Nigerian populations. J Rheumatol 1993; 20: 618-622.
20. Otero, GEO. Estudio epidemiológico: prevalencia de tres enfermedades en el barrio Minuto de Dios de Bogotá. Bogotá: Fundación Instituto de Reumatología e Inmunología, 1986.
21. Anaya JM. ¿Participar, publicar o aportar? El modelo de la investigación en artritis reumatoidea (resumen). Rev Colomb Reumatol. 1997; 4: 111.
22. Rueda Gutiérrez J, González Buriticá H, Abello Banfi M. Evaluación y seguimiento de pacientes con artritis reumatoide. En: Ramírez LA, Anaya JM, eds. Artritis Reumatoide. Medellín, Edimeco, S.A., 1998: 129-145
23. Rasker JJ, Cosh JA. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 1981; 40: 115-120.
24. Reilly PA, Cosh JA, Maddison PJ, et al. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-369.
25. Corbett M, Young A, Dalton D, et al. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993; 32: 717-723.
26. James D, Cox N, Davis P, et al. Major life events as a result of rheumatoid arthritis. A comparison between 9 centres in 446 patients in the first three years of disease. Br J Rheumatol 1995; 34 (suppl): 9.
27. Peña Cortés MA. Mortalidad. En: Peña Cortés MA, ed. Artritis Reumatoidea. Treinta años de experiencia. Editorial Servi Offset, Santafé de Bogotá, 1997: 67-75
28. Gao X, Olsen NJ, Pincus T, Stasny P. HLA-DR alleles with naturally occurring aminoacid substitutions and risk for development of rheumatoid arthritis. Arthritis Rheum 1990; 33: 939-946.
29. Weyand CM, Hicok KG, Conn DL, Goronzy J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Int Med 1992; 117: 801-806.
30. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Cur Opin Rheumatol 1998; 10: 187-200.
31. McDaniel DO, Alarcón GS, Pratt PW, Reveille JD. Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann Intern Med 1995; 123: 181-187
32. Wagner V, Kaltenhauser S, Sauer H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997; 40: 341-351.
33. Collins EJ. Crystallographic analysis of peptide binding by class I and class II major histocompatibility antigens. En: Urban RG,
34. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995; 22: 1032-1036.
35. Hall FC, Weeks DE, Camilleri JP, et al. Influence of the HLA-DRB1 locus on susceptibility and severity in rheumatoid arthritis. QJM 1996; 11: 821-829.
36. Van Jaarseveld CHM, Otten HG, Jacobs JWJ, Kruize AA, Brus HLM, Bijlsma JWJ. Is there an indication for HLA-DR typing for individual patients with rheumatoid arthritis? Clin Exp Rheumatol 1998; 16: 483-488.
37. Teller K, Budhai L, Zhang M, Haramati N, Keiser HD, Davison A. HLA-DRB1 and DQB typing of hispanic american patients with rheumatoid arthritis : the “shared epitope’ hypothesis may not apply. J Rheumatol 1996; 23: 1363-1368.
38. Gonzalez A, Nicovani S, Massardo L, et al. Influence of the HLA-DR? shared epitope on susceptibility to and clinical expression of rheumatoid arthritis in Chilean patients. Ann Rheum Dis 1997; 56: 191-193.
39. Clavijo Acero E, Molina Ramos T, Bernal Gómez A, Pinilla Roa A. Incidencia del HLA en artritis reumatoidea (resumen) Acta Med Colomb 1990; 15(suppl): 267.
40. Yunis JJ, Salazar M, Deulofeut R, et al. DRB1*0404 allele and rheumatoid arthritis in the Guambiano amerindian tribe of Colombia (resumen). Arthritis Rheum 1994; 38(suppl): 4
41. Avila LM, Garzón AM, Talero OH, Reyes E, Valle RR. Estudio inmunogenético en pacientes colombianos con artritis reumatoide (resumen). Rev Colomb Reumatol 1995; 2: 90.
42. Wucherpfenning KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: A mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 1995; 181: 1597-1601.
43. Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J 1998 12: 1255-1265.
44. Gorga JC, Monos D. HLA and disease: molecular basis. En: Urban RG, Chicz RM, eds. MHC Molecules. Expression, Assembly and Function. New York: Chapman & Hall; 1996: 135-162.
45. Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996; 17:466-470.
46. Auger I, Roudier J. A function for the QKRAA amino acid motif: mediating binding of DnaJ to DnaK. J Clin Invest 1997; 99: 1818-1822
47. Kurzik-Dumke U, Schick C, Rzepka R, Melchers I. Overexpression of human homologs of the bacterial DnaJ chaperone in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 210-220.
48. Jawaheer D, Thomson W, MacGregor AJ, et al. «Homozygosity» For the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994; 37: 681-686.
49. Aicher WK, Sakamoto KM, Hack A, Eibel H. Analysis of functional elements in the human Egr-1 gene promoter. Rheumatol Int. 1999; 18: 207-214.
50. Cantagrel A, Navaux F, Loubet-Lescoulie P, et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1093-1100.
51. Carson DA, Haneji N. Fighting arthritis with a senescence gene [news; comment]. Nat Med. 1999; 5: 731-732.
52. De Vries N, van Elderen C, Tijssen H, van Riel PL, van de Putte LB. No support for HLA-DQ S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Ann Rheum Dis. 1999; 58: 164-168.
53. Encoded susceptibility in rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1621-1627.
54. Han Z, Boyle DL, Shi Y, Green DR, Firestein GS. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1088-1092.
55. John S, Myerscough A, Eyre S, et al. Linkage of a marker in intron D of the estrogen synthase locus to rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1617-1620.
56. Kullmann F, Judex M, Neudecker I, et al. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 1999; 42:1594-1600.
57. Matsushita M, Tsuchiya N, Oka T, Yamane A, Tokunaga K. New variations of human SHP-1. Immunogenetics. 1999; 49: 577-579.
58. Mattey DL, Hassell AB, Plant M, et al. Association of polymorphism in glutathione Chicz RM, eds. MHC Molecules. Expression, Assembly and Function. New York: Chapman & Hall; 1996: 113-134.
59. Perdriger A, Guggenbuhl P, Chales G, et al. Positive association of the HLA DMB1*0101-0101 genotype with rheumatoid arthritis. Rheumatology. 1999; 38: 448-452.
60. Ushiyama T, Mori K, Inoue K, Huang J, Nishioka J, Hukuda S. Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Ann Rheum Dis. 1999; 58: 7-10.
61. Cornélis F, Fauré S, Martinez M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. PNAS 1998; 95: 10746-10750.
62. Eskdale J, McNicholl J, Wordsworth P, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 1998; 352:1282-1283.
63. Higami K, Hakoda M, Matsuda Y, Ueda H, Kashiwazaki S. Lack of association of HLA-DRB1 genotype with radiologic progression in Japanese patients with early rheumatoid arthritis. Arthritis Rheum 1997; 40: 2241-2247.
64. Wakitani S, Murata N, Toda Y, et al. The relationship between HLA-DRB1 alleles and disease subsets of rheumatoid arthritis in Japanese. Br J Rheumatol 1997; 36: 630-636.
65. Debaz H, Olivo A, Vázquez García MN, et al. Relevant residues of DRbeta1 third hypervariable region contributing to the expression and to severity of rheumatoid arthritis (RA) in Mexicans. Hum Immunol 1998 59: 287-94.
66. Weyand CM, Schmidt D, Wagner U, Goronzy J. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 1998; 41: 817-822.
67. Brennan P, Hajeer A, Ong KR, et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1383-1386.
68. Gutiérrez MA, Anaya JM, Cabrera GE, Vindrola O, Espinoza LR. Prolactin, a link between neuroendocrine and immune systems. Its role in the pathogenesis of rheumatic diseases. Rev Rhum 1994; 61: 261-267.
69. Spector TD, Perry LA, Tubb G, Silman AJ, Huskisson EC. Low free testosterone levels in males with rheumatoid arthritis. Ann Rheum Dis 1988; 47: 65-68.
70. Ollier W. HLA genes and rheumatoid arthritis susceptibility. En: Day I, Humphries S, eds. Genetic of Common Diseases: future therapeutic and diagnostic possibilities. Oxford: BIOS Scientific, 1998: 171-183.
71. Word Health Organization. International classification of impairments, disabilities and handicaps. Ginebra: World Health Organization; 1980.
72. Pincus T, Callahan LF. How many types of patients meet classification criteria for rheumatoid arthritis?. J Rheumatol 1994; 21: 1385-1389.
73. Pincus T, Brooks RH, Callahan LF. Measures of inflammatory activity in rheumatoid arthritis may indicate no change or improvement over 5 years while measures of damage indicate disease progression: implications for assessment of long-term outcomes (resumen). Arthritis Rheum 1995; 38 (suppl.):S258.
74. Kirwan J. A theoretical framework for process outcome and prognosis in rheumatoid arthritis. J Rheumatol 1992;19:333-6
75. Van der Heijde DMFM. The continuing challenge of predictive factors in rheumatoid arthritis: Prediction or association? J Rheumatol 1997;24:1-8.
76. Laupacis A, Wells G, Richardson WS, Tugwell P. Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 1994 272:3 234-237.
77. Young A, van der Heijde DMFP. Can we predict aggressive disease? Bailliere’s Clin Rheumatol 1997; 11: 27-48.
78. Rodríguez DA, Plata CA, Gutiérrez JM. Validación de la versión colombiana del cuestionario de salud de Stanford. Acta Med Colomb 1998; 23:62-68.
79. Pincus T. Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Rheum Dis Clin NA 1995; 21: 619-654.